Table 1 Characteristics of GIST patients in test and validation cohort without imatinib adjuvant therapy
Test cohort (n = 212) | Validation cohort (n = 158) | Pvalue | |
|---|---|---|---|
Age (years) | |||
≤ 50 | 36 (17.0%) | 37 (23.4%) | 0.124 |
> 50 | 176 (83.0%) | 121 (76.6%) | |
Gender | |||
Male | 114 (53.8%) | 85 (53.8%) | 0.996 |
Female | 98 (46.2%) | 73 (46.2%) | |
Tumor site | |||
Stomach | 129 (60.8%) | 82 (51.9%) | 0.094 |
Small bowel | 48 (22.6%) | 54 (34.2%) | |
Colon | 10 (4.7%) | 8 (5.1%) | |
Others | 25 (11.9%) | 14 (8.9%) | |
Tumor size (cm) | |||
≤ 2.0 | 20 (9.4%) | 16 (10.1%) | 0.408 |
2.1-5.0 | 100 (47.2%) | 61 (38.6%) | |
5.1-10.0 | 59 (27.8%) | 54 (34.2%) | |
> 10.0 | 33 (15.6%) | 27 (17.1%) | |
Mitoses per 50 HPFs | |||
≤ 5 | 175 (82.5%) | 118 (74.7%) | 0.078 |
6-10 | 23 (10.8%) | 19 (12.0%) | |
> 10 | 14 (6.7%) | 21 (13.3%) | |
Modified NIH criteria | |||
Very low risk | 18 (8.5%) | 14 (8.9%) | 0.087 |
Low risk | 96 (45.3%) | 56 (35.4%) | |
Intermediate risk | 38 (17.9%) | 24 (15.2%) | |
High risk | 60 (28.3%) | 64 (40.5%) | |
Serosal invasion | |||
Yes | 23 (10.8%) | 20 (12.7%) | 0.591 |
No | 189 (89.2%) | 138 (87.3%) |